Why is the Mesoblast share price sinking 25% on Tuesday?

This biotech is being sold off today. But why?

The Mesoblast Ltd (ASX: MSB) share price has returned from its trading halt with a bang.

In morning trade, the biotechnology company's shares are down a massive 25% to a decade-low of 30.5 cents.

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.

Image source: Getty Images

Why is the Mesoblast share price sinking?

Investors have been hitting the sell button today after Mesoblast completed yet another capital raising.

With the company struggling to get its stem cell therapies approved by the US Food and Drug Administration it has continued to burn through cash like kindling in recent years.

Unfortunately, this has meant it has needed to tap the market multiple times to keep the lights on at Mesoblast HQ.

On this occasion, the company has received firm commitments for an institutional placement and entitlement offer to raise $55 million at a 26% discount of $0.30 per new share.

Despite how poorly previous capital raisings have turned out for investors, Mesoblast notes that the placement was oversubscribed. The company's CEO, Dr Silviu Itescu, has also committed to taking up a majority of his entitlement.

Dr Itescu commented:

I would like to acknowledge the ongoing support from our key institutional shareholders who have participated alongside myself and welcome new investors in the accelerated component of our placement and entitlement offer. The funds raised will allow Mesoblast to achieve its key objectives for 2024, as outlined at the AGM.

The company will now push on with its retail entitlement offer which is aiming to raise $42 million at the same price. However, given that the offer price is now only a modest discount to where its shares trade, it remains to be seen how popular it will be.

The Mesoblast share price is now down approximately 75% over the last 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »